293 related articles for article (PubMed ID: 32437738)
41. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Sly N; Gaspar K
Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
[TBL] [Abstract][Full Text] [Related]
42. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in
Schneeweiss-Gleixner M; Filik Y; Stefanzl G; Berger D; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Witzeneder N; Greiner G; Hoermann G; Schiefer AI; Schwaab J; Jawhar M; Reiter A; Sperr WR; Arock M; Valent P; Gleixner KV
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804842
[TBL] [Abstract][Full Text] [Related]
43. Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Taylor F; Li X; Yip C; Padilla B; Mar B; Green T; Oren R; Boral AL; Lin HM; Shields AL; Gotlib J
Leuk Res; 2021 Sep; 108():106606. PubMed ID: 34004551
[TBL] [Abstract][Full Text] [Related]
44. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
45. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
[TBL] [Abstract][Full Text] [Related]
46. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Taylor F; Akin C; Lamoureux RE; Padilla B; Green T; Boral AL; Mazar I; Mar B; Shields AL; Siebenhaar F
Orphanet J Rare Dis; 2021 Oct; 16(1):414. PubMed ID: 34627355
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ
Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345
[TBL] [Abstract][Full Text] [Related]
48. Avapritinib for advanced systemic mastocytosis.
Gotlib J; Reiter A; DeAngelo DJ
Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
[TBL] [Abstract][Full Text] [Related]
49. A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis.
Lübke J; Naumann N; Hoffmann O; Horny HP; Sotlar K; Rudelius M; Metzgeroth G; Fabarius A; Hofmann WK; Reiter A; Schwaab J
Sci Rep; 2024 Jan; 14(1):702. PubMed ID: 38184670
[TBL] [Abstract][Full Text] [Related]
50. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Stone RM; Manley PW; Larson RA; Capdeville R
Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
[TBL] [Abstract][Full Text] [Related]
51. Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant.
Martynova A; Nael A; O Neill C; Ramsingh G; Merchant A; Yaghmour B; Yaghmour G
Br J Haematol; 2019 Sep; 186(5):e139-e141. PubMed ID: 31111479
[No Abstract] [Full Text] [Related]
52. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium.
Pyatilova P; Akin C; Alvarez-Twose I; Arock M; Bonadonna P; Brockow K; Butterfield JH; Broesby-Olsen S; Carter MC; Castells M; George TI; Gotlib J; Greiner G; Gülen T; Hartmann K; Hermine O; Horny HP; Jawhar M; Lange M; Lyons JJ; Maurer M; Metcalfe DD; Nedoszytko B; Niedoszytko M; Orfao A; Reiter A; Schwaab J; Sotlar K; Sperr WR; Triggiani M; Valent P; Siebenhaar F
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2015-2024. PubMed ID: 35724950
[TBL] [Abstract][Full Text] [Related]
53. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis.
Riffel P; Schwaab J; Lutz C; Naumann N; Metzgeroth G; Fabarius A; Schoenberg SO; Hofmann WK; Valent P; Reiter A; Jawhar M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):945-951. PubMed ID: 31980928
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
55. Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience.
Farrukh F; Gangat N; Shah MV; Litzow MR; Elliott MA; Begna K; Hook CC; Tefferi A; Pardanani A
Am J Hematol; 2022 Apr; 97(4):E138-E140. PubMed ID: 35015315
[No Abstract] [Full Text] [Related]
56. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
57. Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Galinsky I; Coleman M; Fechter L
Clin J Oncol Nurs; 2019 Dec; 23(6):599-608. PubMed ID: 31730602
[TBL] [Abstract][Full Text] [Related]
58. Measuring Symptom Severity and Quality of Life in Mastocytosis.
Pyatilova P; Siebenhaar F
Immunol Allergy Clin North Am; 2023 Nov; 43(4):751-762. PubMed ID: 37758411
[TBL] [Abstract][Full Text] [Related]
59. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
60. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
